Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Tax Provisions (2021 - 2025)

Historic Tax Provisions for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $56000.0.

  • Aligos Therapeutics' Tax Provisions fell 3846.15% to $56000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $311000.0, marking a year-over-year increase of 1350.36%. This contributed to the annual value of $331000.0 for FY2024, which is 5836.48% down from last year.
  • Latest data reveals that Aligos Therapeutics reported Tax Provisions of $56000.0 as of Q3 2025, which was down 3846.15% from $185000.0 recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Tax Provisions peaked at $757000.0 during Q2 2023, and registered a low of -$58000.0 during Q4 2021.
  • Its 5-year average for Tax Provisions is $87210.5, with a median of $45000.0 in 2021.
  • Examining YoY changes over the last 5 years, Aligos Therapeutics' Tax Provisions showed a top increase of 151063.83% in 2023 and a maximum decrease of 16122.45% in 2023.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Tax Provisions stood at -$58000.0 in 2021, then surged by 184.48% to $49000.0 in 2022, then tumbled by 161.22% to -$30000.0 in 2023, then soared by 190.0% to $27000.0 in 2024, then soared by 107.41% to $56000.0 in 2025.
  • Its last three reported values are $56000.0 in Q3 2025, $185000.0 for Q2 2025, and $43000.0 during Q1 2025.